Articles from Catalyst OrthoScience Inc.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that its Catalyst Fracture Shoulder System has received FDA 510(k) clearance for additional indications that now include anatomic (total or hemi) shoulder procedures, giving surgeons flexibility to treat complex proximal humeral fractures (PHFs) with a single, streamlined platform for both anatomic and reverse replacements. In anatomic indications, the Catalyst Fracture System utilizes Catalyst’s ellipsoid head design, shown to better restore natural anatomy compared to traditional spherical head designs on the market today.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced the close of $15 million in equity and debt financing, led by RC Capital, with participation from Mutual Capital Partners, Dr. Derace Schaffer, and Western Alliance Bank, Member FDIC.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced today the full commercial release of the Catalyst Fracture Shoulder System. While this marks the latest innovation in Catalyst’s expanding portfolio, the company continues to expand its momentum within the orthopedic community – underscored by recently published midterm data from its Catalyst CSR™, which demonstrates industry-leading Single-Assessment Numeric Evaluation (SANE) scores.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, today announced positive, mid-term data reporting on patients treated with its Catalyst CSR™ shoulder system was published in the Journal of Shoulder and Elbow Surgery. This is the ninth peer-reviewed publication for the Catalyst CSR system, which has previously shown to more accurately restore the proximal humerus anatomy1,2,3 with earlier improvements in motion than traditional stemmed and stemless shoulder arthroplasty systems.1 The data from this study introduces a new industry benchmark, showing that patients who underwent anatomic total shoulder arthroplasty (aTSA) with the Catalyst CSR system experienced high patient satisfaction, little to no pain, significant functional improvements, and very low revision rates that exceed the average data published for similar aTSA implants.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced the appointment of Dr. Miguel Ramirez as chief medical officer (CMO), effective immediately. Dr. Ramirez succeeds Dr. Steven Goldberg, Catalyst’s founder, who has stepped down from his roles as CMO and board member but will remain actively engaged, continuing to contribute his expertise and passion for the company.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announced that it has appointed Amy Ables, PhD, as chief commercial officer (CCO) of the organization, effective immediately.

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announces it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) and the first surgeries have been successfully performed for the Catalyst Fracture Shoulder System, a reverse for fracture arthroplasty system to treat proximal humeral fractures (PHFs).

Catalyst OrthoScience Inc. (“Catalyst”), a private medical technology leader focused on shoulder arthroplasty, the fastest growing segment in the orthopedics market, announces it has surpassed 10,000 total shoulder arthroplasty (TSA) procedures as it closes $20 million in equity and venture debt financing with funding partners RC Capital, Mutual Capital Partners and Bridge Bank.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed Amy Ables, Ph.D. as chief strategy officer of the organization, effective immediately.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has appointed seasoned medical device leader Mark Quick as chief financial officer of the organization, effective immediately.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has announced that internationally recognized orthopedic surgeon Theodore Blaine, MD, has completed the first series of total shoulder arthroplasty procedures using the Catalyst Stemmed CSR TSA fully convertible system with an ellipsoid humeral head.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has announced publication of a new study in the Journal of Shoulder and Elbow Surgery that shows positive clinical outcomes using the Catalyst™ CSR total shoulder system, compared to standard stemmed TSAs.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its fully convertible stemmed total shoulder arthroplasty system with an ellipsoid anatomic head. This is the market’s first stemmed arthroplasty system featuring an ellipsoid humeral head, which allows for more accurate restoration of the natural joint kinematics compared to spherical head designs.

Catalyst OrthoScience, a medical device company focused on the upper extremity orthopedics market, is pleased to announce that Dr. Todd Wilson has joined Catalyst as Vice President of Medical Education and Training effective immediately.

Catalyst OrthoScience, a medical device company focused on the upper extremity orthopedics market, is pleased to announce that David Sharp has joined Catalyst as Vice President of Global Marketing effective immediately.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, will be at the American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting, March 23-25, 2022, in Chicago. At booth #2408, Catalyst will have demos and the latest information to share about its latest products, including the Archer CSR Total Shoulder System, Archer R1 Reverse Shoulder System, as well as the Archer 3D Targeting imaging software that supports preoperative planning for shoulder arthroplasty.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced that the platform technology for its Archer™ 3D Targeting planning software received 510(k) clearance for use in shoulder arthroplasty. Licensed in partnership with 3D-Shoulder, a subsidiary of 3D-Side, Archer 3D Targeting is an innovative, preoperative shoulder planning software encompassing both anatomic and reverse planning capabilities.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has named Carl O’Connell as president and chief executive officer effective immediately.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, will provide demonstrations of its innovative Archer™ Shoulder Systems at two major upcoming events: the Orthopaedic Summit 2021, Dec. 11-14 in Las Vegas, Nev. and the 2021 American Shoulder & Elbow Surgeons (ASES) Annual Meeting, Dec. 15-17 in Tampa, Fla.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, has raised $12.3 million in an oversubscribed Series D financing round led by River Cities Capital (River Cities) and Mutual Capital Partners (Mutual Capital).

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, will be at the American Academy of Orthopedic Surgeons (AAOS) 2021 Annual Meeting, September 1-3, 2021, in San Diego. At Booth #3452, Catalyst will host topical presentations by surgical opinion leaders and provide demonstrations of its innovative Archer™ CSR Total Shoulder System and Archer™ R1 Reverse Shoulder System. The company also will preview its recently announced Archer™ 3D Targeting, new imaging software that supports preoperative planning for shoulder arthroplasty.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today introduced a preview of Archer™ 3D Targeting, imaging software designed to support preoperative planning for shoulder arthroplasty. Licensed in partnership with 3D-Shoulder, a subsidiary of 3D-Side, Archer 3D Targeting leverages decades of shoulder experience to help surgeons gain a better understanding of the patient’s pathology and create a surgical plan in advance of the procedure.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, today announced the first surgeries using the new Archer™ R1 Reverse Shoulder System. In March, the company received FDA 510(k) clearance and has kicked off a limited user release in Q2 2021. A commercial launch is planned for later in 2021. With the introduction of the Archer R1 system, Catalyst is addressing the two fastest growing segments of the shoulder arthroplasty market – stemless anatomic and reverse TSA.

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, is introducing its new Archer™ R1 Reverse Shoulder System as its Archer™ CSR Total Shoulder System continues to gain market share.